Article
Cell Biology
Yaschar Kabiri, Anna Fuhrmann, Anna Becker, Luisa Jedermann, Carola Eberhagen, Ann-Christine Koenig, Tiago Barros Silva, Fernanda Borges, Stefanie M. M. Hauck, Bernhard Michalke, Percy Knolle, Hans Zischka
Summary: Inhibiting ALR leads to mitochondrial impairment and proliferation deficits in hepatocellular carcinoma cells, which can be reversed by supplementation with bioavailable hemin b. These findings contribute to a better understanding of the complex relationship between iron and mitochondrial homeostasis in liver cancer.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Instruments & Instrumentation
Song You, Zijin Luo, Niangmei Cheng, Ming Wu, Yongping Lai, Fei Wang, Xiaoyuan Zheng, Yingchao Wang, Xiaolong Liu, Jingfeng Liu, Bixing Zhao
Summary: The study found that high expression of circ_0058051 in hepatocellular carcinoma (HCC) is negatively correlated with patient prognosis. By using a novel siRNA delivery system PPPCSs, knockdown of circ_0058051 can attenuate the proliferation, colony formation, and migration of HCC cells, and inhibit tumor growth through intravenous injection without toxicity to organs in nude mice.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Lu Bai, Siwen Sun, Wenmei Su, Chaoqun Chen, Yuesheng Lv, Jinrui Zhang, Jinyao Zhao, Man Li, Yangfan Qi, Wenjing Zhang, Yang Wang
Summary: Melatonin inhibits the growth of hepatocellular carcinoma by regulating RNA alternative splicing and transcriptional alterations.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Feng Zhang, Jie Gao, Xudong Liu, Yaohui Sun, Long Liu, Bowen Hu, Zhihui Wang, Jihua Shi, Wenzhi Guo, Shuijun Zhang
Summary: Abnormal cholesterol synthesis contributes to the development of hepatocellular carcinoma (HCC). The transcription factor SREBP2 is highly expressed in HCC and is associated with poor prognosis. Inhibition of SREBP2 nuclear translocation suppresses HCC cell migration and invasion via the epithelial-mesenchymal transition (EMT) process. The functional activity of LATS regulates the effects of SREBP2 in HCC.
MOLECULAR CARCINOGENESIS
(2023)
Review
Immunology
Shuyu Liu, Xilan Yang
Summary: The liver is a vital organ in human body, involved in metabolism and detoxification. Liver diseases like hepatitis, cirrhosis, and liver cancer are common and pose a great threat to public health. The development of these diseases is related to persistent liver damage, activation of hepatic stellate cells, and excessive deposition of extracellular matrix. The intestinal flora and its metabolites play a role in the progression of liver disease, but comprehensive reviews on this topic are lacking.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Oncology
Jiaxing Guo, Meiyuan Huang, Shuang Deng, Haiyan Wang, Zuli Wang, Bokang Yan
Summary: In this study, we reveal the previously unrecognized role of RPLP2 in HCC and provide a new regulatory mechanism of ferroptosis, indicating that RPLP2 may be a novel therapeutic target for HCC. Elevated level of RPLP2 is strongly associated with advanced clinicopathologic features and predicts poor prognosis of HCC patients. Inhibition of RPLP2 could lead to the acceleration of ferroptosis to suppress tumor progression of HCC. Drug sensitivity analysis predicts many drugs that potentially target RPLP2.
CANCER CELL INTERNATIONAL
(2023)
Article
Biochemistry & Molecular Biology
Legang Xue, Pei Liu
Summary: The study revealed that Daurisoline (DAS) can enhance the sensitivity of HCC cells to cisplatin chemotherapy by inhibiting lysosomal acidification. In vivo experiments also demonstrated significant suppression of tumor progression when DAS was combined with cisplatin.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Medicine, Research & Experimental
Li Li, Wen-Tao Zuo, Hui Liu, Lan-Shan Liao, Wen-Ying Shen, Zhen-Feng Chen, Hong Liang
Summary: In this study, we synthesized and characterized a oxoaporphine Pr(III) complex that was found to inhibit the progression and metastasis of hepatocellular carcinoma (HCC) by disrupting the communication between HCC cells and macrophages. The complex upregulated certain molecules in macrophages and inhibited their polarization, which significantly inhibited HCC cell proliferation, migration, and invasion. Additionally, the complex inhibited the migration, invasion, and chemotaxis of HCC cells by downregulating the expression of certain markers. Overall, this is the first report of a lanthanide complex exerting regulatory effects on both tumors and tumor-associated macrophages, providing a new strategy for the development of effective antitumor drugs.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Medicine, Research & Experimental
Jia-Peng Lin, Mao-Hua Huang, Zhi-Ting Sun, Lei Chen, Yu-He Lei, Yu-Qing Huang, Ming Qi, Shu-Ran Fan, Shou-Guo Chen, Chi-Wing Chung, Mei-Ching Chan, Jun-Shan Liu, Min Hu, Min-Feng Chen, Wen-Cai Ye, Yue-Yue Chen, Li-Juan Deng
Summary: The study aimed to evaluate the effect of periplocin on inhibiting hepatocellular carcinoma (HCC) and further determine its mechanisms. The findings revealed that periplocin inhibited HCC progression by G2/M arrest, apoptosis, and suppression of myeloid-derived suppressor cells (MDSCs) accumulation through the blockade of the AKT/NF-κB pathway. These results suggest that periplocin has the potential to be developed as an effective therapeutic agent for HCC.
Article
Biotechnology & Applied Microbiology
Hao Shen, Haifeng Li, Jiahua Zhou
Summary: This study found that hsa_circ_0032683 has the ability to inhibit proliferation and promote apoptosis in HCC, by competitively regulating the RTN4 gene. This provides potential therapeutic targets and biomarkers for HCC patients.
Article
Oncology
Tongqing Chen, Dongdong Sun, Qijuan Wang, Tingting Zhou, Jiani Tan, Changliang Xu, Haibo Cheng, Weixing Shen
Summary: The study reveals that alpha-hederin can induce apoptosis and inhibit cell proliferation in hepatocellular carcinoma cells by inhibiting YAP activity, highlighting its potential as an anti-cancer drug for liver cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Environmental Sciences
Shenglan Jia, Mauricius Marques Dos Santos, Caixia Li, Mingliang Fang, Mithusha Sureshkumar, Shane A. Snyder
Summary: This study investigated the effects of three bisphenol analogs (BPAF, BPG, and BPPH) on the metabolic pathways of HepG2 cells. The results showed that these compounds primarily affected energy metabolism, resulting in reduced mitochondrial function and enhanced glycolysis. BPAF had a minor impact on mitochondria but promoted cell proliferation, potentially contributing to energy metabolism dysfunction. In contrast, BPG and BPPH caused severe mitochondrial damage but did not activate estrogen receptor alpha (ER alpha).
ENVIRONMENT INTERNATIONAL
(2023)
Article
Oncology
Zhongyuan Cui, Jielong Wang, Gang Chen, Dongliang Li, Bianqiao Cheng, Yanhua Lai, Zhixian Wu
Summary: This study aimed to identify potential novel prognostic markers and therapeutic targets for hepatocellular carcinoma (HCC). The upregulation of CLGN in HCC was significantly associated with poor prognosis, especially in advanced stages, and may be regulated by hsa-miR-194-3p. These findings suggest that CLGN may be closely related to the progression of HCC, and is a potential therapeutic target and prognostic indicator for patients with advanced HCC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Ji-Hye Choi, So M. Kwon, Sung U. Moon, Sarah Yoon, Masaud Shah, Byoung G. Lee, Jieun Yang, Young N. Park, Hee-Jung Wang, Hyun G. Woo
Summary: Through RNA-Seq analysis, the study identified TPRG1-AS1 as a potential driver noncoding RNA that promotes heterogeneous progression of liver cancer. TPRG1-AS1 induces tumor suppressor RBM24, activating apoptotic tumor cell death to suppress tumor growth, and acts as a ceRNA interfering with the binding of miR-4691-5p and miR-3659 to RBM24.
LIVER INTERNATIONAL
(2021)
Article
Biotechnology & Applied Microbiology
Minan Li, Hong Liao, Jian Wu, Bin Chen, Runhua Pang, Junhai Huang, Yaqing Zhu
Summary: The study found that lncRNA MEG3 inhibits HCC tumorigenesis and progression by modulating the miR-5195-3p/FOXO1 signaling axis. This highlights a potential novel therapeutic target for HCC treatment.
